Management of Immune Checkpoint Inhibitor Toxicities

被引：0

作者：

Durrechou, Quentin ^{[1
]}

Domblides, Charlotte ^{[1
,2
]}

Sionneau, Baptiste ^{[1
]}

Lefort, Felix ^{[1
]}

Quivy, Amandine ^{[1
]}

Ravaud, Alain ^{[1
]}

Gross-Goupil, Marine ^{[1
]}

Daste, Amaury ^{[1
]}

机构：

[1] Univ Bordeaux, CHU Bordeaux, Hop St Andre, Dept Med Oncol, 1 Rue Jean Burguet, F-33000 Bordeaux, France

[2] Bordeaux Univ, CNRS UMR 5164, ImmunoConcEpt, F-33076 Bordeaux, France

来源：

CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷

关键词：

immune check point inhibitor; toxicity; corticosteroids; immunosuppressive treatments; STAGE-III MELANOMA; ADVERSE EVENTS; PREEXISTING AUTOIMMUNE; METASTATIC MELANOMA; COMBINED NIVOLUMAB; OLDER-ADULTS; DOUBLE-BLIND; IPILIMUMAB; CANCER; SAFETY;

D O I：

10.2147/CMAR.S219755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherapy or in combination with other agents. The toxicity profiles of ICIs differ from the side effects of cytotoxic agents and come with new toxicities like immune-related adverse events. Typically, these toxicities occur in all organs. However, the main organs affected are the skin, digestive, hepatic, lungs, rheumatologic, and endocrine. Most of the immune toxicity that occurs is low grade but some more severe toxicities can occur that require a rapid diagnosis and appropriate treatment. The recognition of symptoms by physicians and patient is necessary to resolve them rapidly and adapt treatment to allow the toxicity to resolve.

引用

页码：9139 / 9157

页数：19

共 103 条

[1] Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature [J].

Abdel-Wahab, Noha ;

Safa, Houssein ;

Abudayyeh, Ala ;

Johnson, Daniel H. ;

Van Anh Trinh ;

Zobniw, Chrystia M. ;

Lin, Heather ;

Wong, Michael K. ;

Abdelrahim, Maen ;

Gaber, A. Osama ;

Suarez-Almazor, Maria E. ;

Diab, Adi .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3] Ocular and orbital side-effects of checkpoint inhibitors: a review article [J].

Antoun, Joelle ;

Titah, Cherif ;

Cochereau, Isabelle .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :288-294

[4] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[5] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[6] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[7] Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies [J].

Baldini, Capucine ;

Romano, Patricia Martin ;

Voisin, Anne-Laure ;

Danlos, Francois-Xavier ;

Champiat, Stephane ;

Laghouati, Salim ;

Kfoury, Maria ;

Vincent, Helene ;

Postel-Vinay, Sophie ;

Varga, Andreea ;

Vuagnat, Perrine ;

Ribrag, Vincent ;

Mezquita, Laura ;

Besse, Benjamin ;

Hollebecque, Antoine ;

Lambotte, Olivier ;

Michot, Jean-Marie ;

Soria, Jean-Charles ;

Massard, Christophe ;

Marabelle, Aurelien .

EUROPEAN JOURNAL OF CANCER, 2020, 129 :71-79

[8] Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature [J].

Benfaremo, Devis ;

Manfredi, Lucia ;

Luchetti, Michele Maria ;

Gabrielli, Armando .

CURRENT DRUG SAFETY, 2018, 13 (03) :150-164

[9] Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis [J].

Bergqvist, Viktoria ;

Hertervig, Erik ;

Gedeon, Peter ;

Kopljar, Marija ;

Griph, Hakan ;

Kinhult, Sara ;

Carneiro, Ana ;

Marsal, Jan .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) :581-592

[10] TUMOR-ANTIGENS RECOGNIZED BY T-LYMPHOCYTES [J].

BOON, T ;

CEROTTINI, JC ;

VANDENEYNDE, B ;

VANDERBRUGGEN, P ;

VANPEL, A .

ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :337-365

← 1 2 3 4 5 6 7 8 9 10 →